OGN
Organon & Co.
Drug Manufacturers - General · Healthcare · United States
13.81
close · 2026-10-29
value
88
cheaper than peers88
quality
49
stronger fundamentals49
ranked against
Healthcare
value
quality
547 peerssector comparisonwide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 3.79× | 96 |
| price to sales | 0.58× | 90 |
| EV to EBITDA | 6.90× | 82 |
| price to book | 3.60× | 45 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 34.0% | 94 |
| operating margin | 18.7% | 88 |
| revenue growth | -3.5% | 22 |
| debt to equity | 948.9% | 3 |
4 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | $529.1M |
| employees | 10,000 |
| first trade | 2021-05-14 |
| next earnings | 2026-07-31 |
| fundamentals updated | 2026-07-31 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.72 | 3.33 | 3.99 | 3.59 |
| free cash flow | $384.0M | $588.0M | $538.0M | $431.0M |
| net income | $187.0M | $864.0M | $1.02B | $917.0M |
| revenue | $6.22B | $6.40B | $6.26B | $6.17B |
| unusual items | -$416.0M | -$138.0M | -$112.0M | -$146.0M |